Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.59 |
| ▸ | MLNR | O43193 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | UBE2M | P61081 | 1/20 | 0.45 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.45 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21958743 | 0.91 | EPHX2 (0.70) | EPHX2MLNRKMT2AMEN1UBE2M | |
| SCHEMBL25785128 | 0.91 | EPHX2 (0.52) | EPHX2MLNRKMT2AMEN1UBE2M | |
| SCHEMBL25785131 | 0.85 | TEAD1 (0.59) | EPHX2MLNRKMT2ADCUN1D1TEAD1 | |
| SCHEMBL25785164 | 0.85 | EPHX2 (0.61) | EPHX2MLNRKMT2AMEN1UBE2M | |
| SCHEMBL25785151 | 0.85 | EPHX2 (0.61) | EPHX2MLNRKMT2AMEN1UBE2M | |
| SCHEMBL21958169 | 0.80 | MLNR (0.56) | EPHX2MLNRKMT2AMEN1UBE2M | |
| SCHEMBL9310541 | 0.78 | LMNA (0.59) | EPHX2MLNRKMT2AMEN1UBE2M | |
| SCHEMBL21856356 | 0.77 | EPHX2 (0.57) | EPHX2MLNRKMT2AMEN1UBE2M | |
| SCHEMBL21856361 | 0.77 | EPHX2 (0.57) | EPHX2MLNRKMT2AMEN1UBE2M | |
| SCHEMBL18466043 | 0.77 | EPHX2 (0.54) | EPHX2MLNRKMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | EPHX2 2101/4885MLNR 4328/4885KMT2A 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.